In this phase @ , open-label study , we randomly assigned @ previously untreated patients with HCV genotype @ infection without cirrhosis to receive ledipasvir and sofosbuvir ( ledipasvir-sofosbuvir ) for @ weeks , ledipasvir-sofosbuvir plus ribavirin for @ weeks , or ledipasvir-sofosbuvir for @ weeks .